Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomized controlled trial

Cancer

Volumn 77, Issue 5, 1996, Pages 941-948

  Mantovani, Giovanni ^a   Macciò, Antonio ^a   Bianchi, Alessandro ^a   Curreli, Luigi ^a   Ghiani, Massimo ^a   Proto, Ernesto ^a   Santona, Maria C ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

5 HT3 receptor antagonists; acute nausea; cisplatin; granisetron (GRA); head and neck cancer patients; ondansetron (OND); tropisetron (TRO); vomiting

Indexed keywords

CISPLATIN; GRANISETRON; ONDANSETRON; SEROTONIN ANTAGONIST; TROPISETRON;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANISETRON; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; PROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0030032559     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.0.CO;2-2     Document Type: Article

References (34)

1. Whitehead VM. Cancer treatment needs better antiemetics. N Engl J Med 1975;293:199-200.
2. Andrews PLR, Rareport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988;9:334-41.
3. 3 receptor antagonists. Support Care Cancer 1994;2:286-92.
4. Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Support Care Cancer 1994;2:293-6.
5. Dilly SG. Are granisetron and ondansetron equivalent in the clinic? Eur J Cancer 1992;28A Suppl 1:32S-35S.
6. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study. Eur J Cancer 1993;29A:1669-72.
7. 3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. Proc Am Soc Clin Oncol 1994;13:428.
8. 3 Receptors. Ann Oncol 1994;5 Suppl 8:204.
9. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992;340:96-9.
10. Chevallier B on the behalf of the Granisetron Study Group. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in single-blind study. Eur J Cancer 1990;26 Suppl 1:33-6.
11. 3 antagonists fully cross resistant? A pilot experience. Eur J Cancer 1993;29A Suppl 6:265S.
12. Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F. Granisetron (Gra) vs Ondansetron (Ond) in the prevention of cis-platinum-induced emesis. An open randomized cross-over study. Proc Am Soc Clin Oncol 1994;13:431.
13. Pellier P, Dilly SG, Friedman C, Yocom K. Crossover analysis of efficacy and side effects of granisetron and ondansetron. Proc Am Soc Clin Oncol 1994;13:441.
14. Riess H, Drechsler S, Evers C, Faerber L. Tropisetron (Tro) vs. Ondansetron (Ond) in prophylaxis of chemotherapy-induced emesis (CE). Eur J Cancer 1993;29A Suppl 6:211S.
15. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Selved P, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992;66:192-7.
16. Dogliotti L, Antonacci RA, Pazè E, Ortega C, Berruti A, Faggiuolo R. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Drug 1992;43 Suppl 3:6-10.
17. Soukop M on the behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26:15S-19S.
18. Smith IE on the behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1390;26:19S-23S.
19. Ruff P, Paska W, Goedhals L, Puillard P, Riviere A, Vorobiof D, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double blind, randomized, parallel-group study. Oncology 1994;51:113-8.
20. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994;74:1945-52.
21. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials. A review. Ann Oncol 1991;2:107-14.
22. Joss RA, Brand BC, Buser KS. Cerny T. The symptomatic control of cytostatic drug-induced emesis. A recent history and review. Eur J Cancer 1990;26 Suppl 1:2S-8S.
23. Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986;70:555-63.
24. Pater JL, Willan AR. Methodologic issues in trials of antiemetics. J Clin Oncol 1984;2:484-7.
25. D'Acquisto RW, Tyson LB, Gralla RJ, Clark RA, Kris MG, von Witte DM, et al. The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1986;5:257.
26. Walsh TD. Antiemetic drug combinations in advanced cancer. Lancet 1982;i:1018.
27. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989;7:1693-700.
28. Roua F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R, et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep 1985;69:1353-7.
29. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, et al. Improved control of cisplatin induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985;55:527-34.
30. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 1990;322:810-6.
31. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study. Eur J Cancer 1994;30A:1041-2.
32. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Drug Saf 1994;9:410-28.
33. Dilly SG on the behalf of the Granisetron Study Group. A double-blind cross-over study to compare the efficacy and safety of granisetron and ondansetron in the prophylaxis of nausea and vomiting induced by 5-day fractionated chemotherapy [abstract book]. Proceedings of the Antiemetic Control: Maximizing the Benefits Satellite Symposium to the 7th European Conference on Clinical Oncology and Cancer Nursing; 1993 Nov 14-18; Jerusalem. Macclesfield (UK): Adelphy Communication, 1993:25-7.
34. Gralla RJ. Antiemetic treatment for cancer chemotherapy: problems and progress. Support Care Cancer 1994;2:275-6.